Drugs Containing Excipient (Inactive Ingredient) MAGNESIUM HYDROXIDE

« Back to Dashboard

Branded drugs containing MAGNESIUM HYDROXIDE excipient, and estimated key patent expiration / generic entry dates

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Rebel Distributors Corp	ZMAX	azithromycin	21695-444	MAGNESIUM HYDROXIDE

Generic drugs containing MAGNESIUM HYDROXIDE excipient

Company	Ingredient	NDC	Excipient
Haleon US Holdings LLC	dextromethorphan hydrobromide, guaifenesin	0031-8765	MAGNESIUM HYDROXIDE
L Perrigo Company	dextromethorphan hbr, guaifenesin	0113-0812	MAGNESIUM HYDROXIDE
L Perrigo Company	dextromethorphan hydrobromide, guaifenesin	0113-2219	MAGNESIUM HYDROXIDE
L Perrigo Company	dextromethorphan hydrobromide, guaifenesin	0113-7419	MAGNESIUM HYDROXIDE
L Perrigo Company	dextromethorphan hbr, guaifenesin	0113-7812	MAGNESIUM HYDROXIDE
Bayer HealthCare LLC	dextromethorphan hydrobromide, guaifenesin	0280-1660	MAGNESIUM HYDROXIDE

Magnesium Hydroxide Pharmaceutical Excipient Market Dynamics and Financial Trajectory

Last updated: October 2, 2026

Magnesium hydroxide is a low-cost, high-volume pharmaceutical material used primarily as an oral antacid and osmotic laxative, with secondary roles as a pH modifier, alkalizing agent, and suspension component. Its pharmaceutical economics are driven more by mineral feedstock, purity grades, energy, freight, and contract manufacturing than by patent exclusivity. The market has limited standalone financial disclosure because producers generally report magnesium hydroxide within broader magnesium compounds, specialty minerals, or pharmaceutical ingredient segments.

Demand should remain stable rather than high-growth. Volume is supported by chronic use in over-the-counter antacid and laxative products, generic oral suspensions, chewable tablets, and combination gastrointestinal medicines. Margin expansion depends on pharmaceutical-grade qualification, particle-size control, contaminant management, and formulation services rather than the commodity powder itself.

What is magnesium hydroxide and how is it used in pharmaceuticals?

Magnesium hydroxide is an inorganic compound with the formula Mg(OH)2, CAS No. 1309-42-8, and a molecular weight of 58.32 g/mol. It is commonly supplied as a white powder or as an aqueous suspension known commercially as milk of magnesia.

In pharmaceutical products, magnesium hydroxide is used in four principal ways:

Pharmaceutical role	Typical product application	Commercial significance
Antacid active ingredient	Oral suspensions, chewable tablets, combination antacids	Largest established pharmaceutical use
Laxative active ingredient	Oral suspensions and liquid products	Stable OTC demand
Alkalizing and pH-adjusting agent	Oral and topical formulations	Smaller, formulation-specific demand
Suspension and processing component	Liquid dosage forms requiring controlled settling and redispersion	Creates demand for particle engineering and quality control

The regulatory distinction matters. Magnesium hydroxide is often described commercially as an excipient, but in antacid and laxative products it is an active pharmaceutical ingredient under applicable FDA OTC monographs. A manufacturer selling it into those products must therefore support active-ingredient specifications, identity, purity, microbial controls, and quality documentation, not only conventional excipient documentation.

The United States Pharmacopeia-National Formulary includes a magnesium hydroxide monograph. Relevant specifications typically address identification, assay, alkalinity, soluble substances, limits on impurities, loss on drying, and physical characteristics. The exact release specification depends on the applicable compendial monograph and customer dossier.

How large is the magnesium hydroxide pharmaceutical market?

No major public company separately reports revenue for pharmaceutical-grade magnesium hydroxide. Market-research estimates for the global magnesium hydroxide market usually combine several end uses, including flame retardants, wastewater treatment, chemical processing, agriculture, and pharmaceuticals. Those estimates should not be treated as pharmaceutical-market revenue.

The pharmaceutical segment is structurally smaller than industrial demand but has better qualification economics. A pharmaceutical customer may pay a substantial premium for:

• GMP manufacturing and audit history.
• USP-NF or equivalent compendial compliance.
• Low heavy-metal and trace-element levels.
• Controlled particle-size distribution.
• Microbial and endotoxin controls where applicable.
• Batch-to-batch suspension performance.
• Regulatory support for drug-master-file or customer filing requirements.
• Long-term supply continuity.

The market therefore has two distinct layers:

Layer	Product economics	Competitive basis
Commodity magnesium hydroxide	Low unit value, high price sensitivity	Mineral access, process yield, energy, logistics
Pharmaceutical-grade material	Higher value per kilogram and lower customer substitution	Qualification, documentation, consistency, regulatory support

Pharmaceutical demand is unlikely to transform the overall magnesium hydroxide industry. It can, however, improve producer margins when a supplier converts industrial-grade capacity into validated pharmaceutical production.

What drives demand for pharmaceutical magnesium hydroxide?

OTC antacid and laxative consumption

The core demand base is mature and recurring. Magnesium hydroxide is present in branded and private-label products sold through pharmacies, mass retailers, grocery channels, and e-commerce. Demand is linked to gastrointestinal symptom treatment, household medicine purchases, and private-label substitution.

The category benefits from:

• Low consumer price points.
• Long shelf life.
• Established physician and consumer familiarity.
• Limited clinical differentiation between qualified suppliers.
• Continued use in generic and store-brand products.

Growth is constrained by competition from calcium carbonate, aluminum hydroxide, magnesium carbonate, magnesium oxide, sodium bicarbonate, proton-pump inhibitors, H2 antagonists, and combination products.

Liquid dosage forms

Suspensions are commercially important because magnesium hydroxide has low water solubility and is commonly delivered as a dispersed solid. Liquid products require control of sedimentation, viscosity, redispersibility, taste, fill uniformity, and container compatibility.

This shifts value toward manufacturers that can provide consistent particle morphology and dispersion performance. A material that meets chemical assay requirements but produces unstable or poorly redispersible suspensions may fail customer qualification.

Generic and private-label manufacturing

Magnesium hydroxide is widely compatible with generic and private-label products. The active ingredient is not generally a major barrier to entry. Finished-product manufacturers can often qualify multiple sources, although switching suppliers may require comparative testing, stability work, process validation, and regulatory documentation.

Private-label growth can increase volume while compressing prices. Branded products may support higher pricing through packaging, formulation, and channel position rather than through exclusivity around magnesium hydroxide itself.

How is pharmaceutical magnesium hydroxide manufactured?

Commercial production uses several feedstocks and process routes:

1. Calcined or processed magnesium minerals, including brucite.
2. Magnesium chloride or magnesium sulfate brines.
3. Seawater or concentrated saline streams.
4. Precipitation through reaction with calcium hydroxide or other alkaline agents.
5. Washing, filtration, drying, milling, classification, and packaging.

The process route affects impurity profile, particle size, morphology, bulk density, surface area, and suspension behavior. Pharmaceutical customers may favor a supplier with a controlled precipitation process even when the chemical formula is identical to lower-grade material.

What manufacturing barriers affect supply?

Manufacturing barriers are moderate rather than high. The chemical synthesis is established, but pharmaceutical qualification creates operational barriers in four areas:

• Raw-material control: Trace metals, calcium, chlorides, sulfates, and insoluble residues can affect compliance.
• Particle engineering: Milling and classification influence mouthfeel, sedimentation, and dosage uniformity.
• Validation: Customers require consistent commercial-scale performance.
• Quality systems: GMP controls, change control, deviation management, and supply documentation influence vendor approval.

Energy prices matter because drying, calcination, milling, and packaging can be significant cost components. Freight also affects delivered economics because magnesium hydroxide is a relatively low-value, high-weight material.

What is the financial trajectory for magnesium hydroxide suppliers?

The financial trajectory is best characterized as stable volume with selective margin improvement, not rapid pharmaceutical market expansion.

Financial driver	Near-term direction	Effect on suppliers
OTC antacid and laxative volume	Stable to modest growth	Supports recurring base demand
Raw-material and energy costs	Volatile	Can compress margins under fixed-price contracts
Pharmaceutical-grade qualification	Positive	Raises switching costs and pricing power
Private-label competition	Negative for pricing	Transfers value toward efficient producers
Specialty particle engineering	Positive	Creates differentiated margins
Freight and packaging	Regionally variable	Affects delivered cost and working capital
Regulatory documentation	Increasing	Raises overhead but supports customer retention
Industrial magnesium hydroxide demand	Cyclical by end market	Can affect capacity allocation and plant utilization

A producer with integrated mineral access and multiple end markets can absorb demand swings better than a pharmaceutical-only supplier. Diversification also allows the company to operate the same production assets across water treatment, flame retardants, chemical processing, agriculture, and healthcare grades.

The strongest financial model is generally a tiered portfolio:

• Industrial-grade magnesium hydroxide for base-load utilization.
• Pharmaceutical-grade material for qualification-based premiums.
• Customized particle-size products for liquid and solid dosage forms.
• Technical support and regulatory packages for strategic customers.

Pure commodity exposure carries greater margin risk. Pharmaceutical qualification reduces price competition but does not eliminate it because the underlying chemistry is widely available.

Which companies compete in the magnesium hydroxide market?

Competition is fragmented across regional mineral processors, specialty chemical companies, and pharmaceutical excipient suppliers. Relevant companies and product families may include:

Company or group	Competitive position
Nikunj Chemicals	Magnesium hydroxide and pharmaceutical-material supply from India
Konoshima Chemical	Specialty magnesium compounds and high-purity materials
Martin Marietta Magnesia Specialties	Magnesium hydroxide and magnesium compounds for industrial and specialty uses
Nedmag	Magnesium compounds derived from brine and mineral resources
Kyowa Chemical Industry	High-purity magnesium compounds and functional inorganic materials
U.S. Magnesium and other integrated producers	Magnesium feedstock and compound supply in selected markets
Regional excipient distributors	Local inventory, documentation, and customer service rather than primary production

The actual competitive set varies by geography, dosage form, and customer qualification. A large pharmaceutical buyer may source directly from a producer, while smaller generic manufacturers often purchase through distributors.

What patents protect magnesium hydroxide formulations?

The base compound has no meaningful modern composition-of-matter exclusivity. Magnesium hydroxide is a long-established inorganic substance, and its use as an antacid or laxative is broadly known.

Patent value may arise from:

• Controlled particle-size distributions.
• Surface-treated magnesium hydroxide.
• Improved suspension stability.
• Reduced gritty mouthfeel.
• Taste-masked or flavored liquid formulations.
• Combination products with aluminum hydroxide, calcium carbonate, simethicone, or other actives.
• Modified-release or dosage-form technologies.
• Manufacturing processes that reduce impurities or improve morphology.
• Packaging systems that preserve suspension uniformity.

These rights usually protect a finished formulation or process, not the purchase of ordinary magnesium hydroxide powder. Patent risk is therefore product-specific.

Are Paragraph IV challenges relevant?

Paragraph IV litigation is relevant to branded finished drug products containing magnesium hydroxide when a listed patent covers a formulation, combination, delivery system, or method of use. It is not generally relevant to the unpatented magnesium hydroxide molecule as a bulk material.

A generic applicant could challenge an Orange Book-listed patent covering a finished antacid or laxative product. The challenge would target the listed product patent, not the basic chemical identity of magnesium hydroxide.

What is the FDA regulatory status of magnesium hydroxide?

Magnesium hydroxide is recognized in FDA OTC frameworks for antacid and laxative use, subject to applicable conditions, labeling, dosage, and formulation requirements. FDA’s OTC drug review system and relevant sections of the Code of Federal Regulations govern these products [1, 2].

For pharmaceutical supply, customers generally evaluate:

• USP-NF compliance.
• FDA establishment and product documentation, where applicable.
• Current Good Manufacturing Practice controls.
• Supplier qualification and audit history.
• Change-control procedures.
• Elemental impurity risk under ICH Q3D.
• Microbial quality for aqueous suspensions.
• Stability and container-closure compatibility.

The supplier’s regulatory burden depends on whether it sells the material as an API, excipient, or component of a finished OTC drug. The same physical material may require different documentation packages for different customers.

What is the Orange Book status of magnesium hydroxide products?

The Orange Book does not create a patent estate around magnesium hydroxide as a chemical substance. Orange Book relevance depends on individual approved finished drug products and whether the sponsor has listed patents for those products.

For an antacid or laxative containing magnesium hydroxide, the commercial assessment should examine:

1. Whether the product is approved under an NDA or marketed under an OTC monograph pathway.
2. Whether the sponsor has listed formulation, combination, or delivery patents.
3. Whether exclusivity remains active.
4. Whether an ANDA pathway is available.
5. Whether state and federal OTC requirements affect launch timing.

Many magnesium hydroxide products compete in a mature, low-barrier category where brand strength, distribution, and manufacturing cost are more important than patent exclusivity.

How does magnesium hydroxide compare with competing antacid ingredients?

Ingredient	Main advantage	Main limitation
Magnesium hydroxide	Established antacid and laxative activity; low raw-material cost	Suspension handling; diarrhea risk at higher exposure
Aluminum hydroxide	Antacid activity and established use	Constipation risk; aluminum impurity scrutiny
Calcium carbonate	High acid-neutralizing capacity; tablet-friendly	Calcium load and rebound-acid considerations
Magnesium oxide	High magnesium content and low cost	Different dissolution and formulation behavior
Sodium bicarbonate	Rapid neutralization	Sodium load and gas formation
Magnesium carbonate	Flexible formulation option	Different solubility and processing profile
Combination antacids	Balances gastrointestinal effects	More complex formulation and regulatory work

Magnesium hydroxide remains competitive because it can address both acid neutralization and constipation in some products. Its principal formulation disadvantage is the need to manage suspension stability and palatability.

What generic launch risks exist?

Generic and private-label launch risk is moderate. The active ingredient itself presents limited patent risk, but a finished-product entrant may face:

• Formulation equivalence requirements.
• Suspension redispersion and dose-uniformity testing.
• Taste and mouthfeel challenges.
• Stability failures.
• Container-closure compatibility issues.
• Supplier qualification delays.
• Shortages or allocation during raw-material disruptions.
• Retailer requirements for low-cost, high-service supply.

A successful entrant usually competes through manufacturing efficiency, reliable supply, packaging, and retailer access. The cost of the magnesium hydroxide ingredient is unlikely to determine the entire product margin, but it can affect profitability in high-volume, low-price SKUs.

What licensing deals and settlement agreements affect the market?

Licensing and settlement activity is more likely to occur at the finished-product level than at the excipient level. Relevant transactions may involve:

• Private-label supply agreements.
• Contract manufacturing arrangements.
• Rights to branded OTC products.
• Formulation licenses.
• Regional distribution agreements.
• Technology licenses for suspension or taste-masking systems.

Bulk magnesium hydroxide producers generally compete through supply contracts rather than publicly announced patent licenses. Settlement agreements would usually relate to a branded formulation patent and an ANDA entrant, not to the underlying excipient or active ingredient.

What is the geographic outlook?

North America

North America has mature OTC demand, high retailer concentration, and strict supplier qualification. Growth is likely to come from private-label products, contract manufacturing, and formulation upgrades rather than large increases in underlying consumer demand.

Europe

European demand is supported by established gastrointestinal medicines and pharmacy channels. Regulatory expectations for excipient quality, traceability, and impurity control are significant. Regional supply and transport costs influence sourcing decisions.

Asia-Pacific

Asia-Pacific is the most important region for capacity expansion, generic manufacturing, and pharmaceutical ingredient sourcing. India and China provide large manufacturing bases, while Japan and South Korea have established specialty chemical capabilities. Price competition is stronger, but pharmaceutical-grade qualification can create export opportunities.

Latin America and other markets

Demand is linked to OTC self-medication, local manufacturing, and imported finished products. Distributor inventory and currency movements can have a greater effect on pricing than changes in the underlying ingredient market.

How strong is the magnesium hydroxide patent estate?

The patent estate for the base material is weak because the compound is old and broadly known. The estate for specific formulations can be moderate, particularly where patents claim:

• Narrow particle-size ranges.
• Suspension systems.
• Taste-masking approaches.
• Combination products.
• Specialized manufacturing processes.
• Device or packaging configurations.

The strongest practical barriers are usually regulatory and commercial rather than legal. Customer qualification, supply continuity, quality history, and retailer relationships can delay substitution even when no enforceable patent blocks entry.

Key Takeaways

• Magnesium hydroxide is both a pharmaceutical ingredient and, depending on the product, an active OTC drug substance.
• Its core uses are antacid and laxative products, with secondary use as an alkalizer and formulation component.
• Public financial reporting does not isolate pharmaceutical-grade magnesium hydroxide revenue.
• The market has stable demand, low molecular patent risk, and moderate manufacturing barriers.
• Margin depends on GMP capability, impurity control, particle engineering, documentation, and logistics.
• Finished-product patents may cover formulations, combinations, suspension systems, or delivery technologies.
• Paragraph IV litigation and Orange Book analysis apply to specific branded products, not to ordinary magnesium hydroxide powder.
• The best supplier economics come from integrated mineral access, diversified end markets, and pharmaceutical-grade qualification.
• Generic entry risk is moderate for finished products and low for the base ingredient, subject to formulation and regulatory requirements.
• Geographic growth is strongest in pharmaceutical manufacturing hubs, particularly Asia-Pacific, but pricing remains competitive.

FAQs

Is magnesium hydroxide an excipient or an active pharmaceutical ingredient?

It can be either. In antacid and laxative products, magnesium hydroxide is generally the active ingredient. In other formulations, it may function as a pH modifier, alkalizer, or processing component.

Does magnesium hydroxide have composition-of-matter patent protection?

No meaningful modern composition-of-matter protection covers the basic compound. Patent protection may apply to specific formulations, particle characteristics, combinations, or manufacturing processes.

Can pharmaceutical manufacturers switch magnesium hydroxide suppliers easily?

Chemical substitution is usually straightforward, but commercial switching requires supplier qualification, comparative testing, stability review, change control, and confirmation that the new material performs equivalently in the finished dosage form.

What is the largest cost risk for magnesium hydroxide producers?

Energy, feedstock, drying, freight, and packaging costs are the principal risks. In pharmaceutical grades, quality-system overhead and failed customer qualification can also affect margins.

Are biosimilar risks relevant to magnesium hydroxide?

No. Magnesium hydroxide is a small inorganic compound, not a biologic. Biosimilar pathways do not apply. Competition occurs through generic, OTC, private-label, and contract-manufacturing channels.

References

1. U.S. Food and Drug Administration. (2022). Antacid products for over-the-counter human use: 21 C.F.R. Part 331. Code of Federal Regulations.

2. U.S. Food and Drug Administration. (2022). Laxative drug products for over-the-counter human use: 21 C.F.R. Part 334. Code of Federal Regulations.

3. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary: Magnesium hydroxide monograph. U.S. Pharmacopeial Convention.

4. U.S. Food and Drug Administration. (2016). Q3D elemental impurities: Guidance for industry. FDA.

5. U.S. Geological Survey. (2024). Mineral commodity summaries: Magnesium compounds. U.S. Department of the Interior.

6. European Medicines Agency. (2015). Guideline on the specification limits for residues of metal catalysts or metal reagents. EMA.